Navigation Links
Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer
Date:5/21/2013

BURLINGTON, Mass., May 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of an emerging agent on key efficacy endpoints, including overall survival and time to disease progression, has the most influence over surveyed U.S. and European oncologists' prescribing decisions for advanced/metastatic hormone-receptor (HR-) positive, HER2-negative breast cancer. The two novel emerging therapies palbociclib (Pfizer's PD-0332991) and buparlisib (Novartis's BKM-120), both in combination with currently available hormonal therapies, are set to offer efficacy advantages over currently available agents used to treat this patient population.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Decision Base 2013 report entitled Breast Cancer (Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic): What Attributes will Distinguish Emerging Therapies in the Eyes of Oncologists and Payers?, finds that surveyed U.S. oncologists would prescribe palbociclib to 50 percent of their first-line advanced/metastatic HR-positive, HER2-negative breast cancer patients.

The report also finds that surveyed managed care organization (MCO) pharmacy directors are particularly receptive to novel therapies that offer an improvement in overall response rate (ORR) in this patient population. However, while several emerging therapies hold promise, Decision Resources does not expect any will match the clinical improvement in ORR over current therapies that surveyed U.S. payers indicated would be necessary for widespread inclusion on MCO formularies.

"This population represents a large and therefore potentially lucrative market segment for drug developers," said Decision Resources Principal Analyst Amy Duval . "The majority of hormonal therapies used to treat patients in this population are generic, and market dynamics had been stagnating until last year's approval of everolimus (Novartis's Afinitor) in this population. Uptake of everolimus and the development of promising late-stage clinical prospects such as palbociclib and buparlisib are set to reinvigorate this market segment."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Next Generation Pharmaceutical Manufacturing Summit Pushes the Envelope of Thought-Leadership at its September Summit in London
2. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
3. Ludlow Research Issues Opinion on PMBS Based on Low Market Cap Valuation
4. For Osteoporosis and Osteopenia, Clinical Data and Thought Leaders Opinions Indicate that AMG-785/CDP-7851 and Odanacatib Have Advantages Over Alendronate
5. In Pretreated Advanced Renal Cell Carcinoma, Thought Leaders Opinions and Clinical Data Indicate that Tivopath Has Efficacy and Tolerability Advantages Over Currently Used Therapies
6. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
7. Active Lifes BioDent Reference Point Indenter Validated in Study Published by Osteoporosis Medical Opinion Leaders
8. Albireo Receives Positive Opinion for Orphan Drug Designation for A4250 for Severe Liver Diseases
9. Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions
10. Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR
11. A*STAR and Cytos Bring Singapores First Influenza Vaccine to Clinical Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2, 2016 On Thursday, December ... excellence in research, development and innovation in the biopharmaceutical ... was held in the presence of Sergey Tsyb, Vice ... Russian Federation , Natalia Sanina, First Vice Chairman ... , Head of Roszdravnadzor, National Service of Control in ...
(Date:12/2/2016)... Dec. 2, 2016 CVS Health Corporation (NYSE: ... Day in New York City on Thursday, December 15, 2016, beginning at 8:00 ... team will provide an in-depth review of the company,s ... The company will also discuss 2017 earnings guidance during ... of the event will be broadcast simultaneously on the ...
(Date:12/2/2016)... YORK , December 2, 2016 ... the trading session in red, while the Dow Jones Industrial ... at the close of US markets, which prompted Stock-callers this ... stocks: NuVasive Inc. (NASDAQ: NUVA ), Smith & ... (NASDAQ: NXTM ), and Cesca Therapeutics Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a ... No other wearable health technology on the market can deliver all that rejiva can. ... meaningful insights about their health than the usual heart rate and steps taken”, adds ...
(Date:12/2/2016)... ... 02, 2016 , ... On November 24th, 2016, Thanksgiving morning, ... different sites throughout Miami-Dade and Broward counties. This is the largest meal delivery ... Thanksgiving morning by putting together individual meals via assembly lines and passing them ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... that we have been designated as a Cigna Infertility Center of Excellence. The ... performance standards. , “It’s an honor to be designated a Cigna Infertility ...
(Date:11/30/2016)... Gardens, FL (PRWEB) , ... November 30, 2016 ... ... eating disorder and mental health treatment has announced the opening of a new ... specialized partial hospitalization and intensive outpatient treatment for adults and adolescents, both males ...
(Date:11/30/2016)... Austin, TX (PRWEB) , ... November 30, 2016 ... ... like to remind the clinical research community that the FDA Binding Guidance goes ... submit data in FDA-supported formats listed in the FDA Data Standards Catalog. The ...
Breaking Medicine News(10 mins):